title: [Study on effect of lentinan in enhancing anti-tumor action of dendritic cytoma vaccine and its mechanism].
abstract: OBJECTIVE
  To improve the anti-tumor effect of dendritic cytoma vaccine (DCV) for finding an effective anti-tumor biotherapy.
  
  
  METHODS
  DC vaccine prepared by transfection of adenovirus mediated melanoma-associated antigen gene (gp100) into bone marrow-derived dendritic cell (DC) was used to study the immuno-therapeutic effect and the mechanism of lentinan (LNT) in different dosages, used alone or combined with gp100-DC for treatment of B16 melanoma bearing mice.
  
  
  RESULTS
  After being treated with LNT combining gp100-DC, the growth of malignant melanoma was inhibited with the tumor-free survival in the experimental animals being 66.7%. The treatment could also significantly enhance the activity of cytotoxicity T lymphocyte (CTL) and natural killer (NK) cells, elevate the levels of interleukin-2 (IL-2) and interferon-gamma (IFN-gamma) in splenocytes, and histological examination showed that a large amount of inflammatory cells infiltrated inside and around the tumor, and obvious necrosis of tumor cells was found.
  
  
  CONCLUSIONS
  By combined use with LNT the anti-tumor immuno-reaction of DCV vaccine could be enhanced effectively.
authors.affiliation: Hangzhou Red Cross Hospital, Zhejiang.
authors.forename: Jun
authors.initials: J
authors.lastname: Wang
authors.forename: Zhi-dong
authors.initials: ZD
authors.lastname: Zhou
authors.forename: Da-jing
authors.initials: DJ
authors.lastname: Xia
mesh_terms: D000276:Adjuvants, Immunologic / Q000494:pharmacology / Q000627:therapeutic use; D000818:Animals; D000972:Antineoplastic Agents, Phytogenic / Q000494:pharmacology / Q000627:therapeutic use; D019496:Cancer Vaccines / Q000008:administration & dosage / Q000276:immunology*; D002460:Cell Line; D045744:Cell Line, Tumor; D003131:Combined Modality Therapy; D003713:Dendritic Cells / Q000166:cytology / Q000276:immunology*; D005260:Female; D006801:Humans; D007912:Lentinan / Q000494:pharmacology* / Q000627:therapeutic use; D008546:Melanoma, Experimental / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D008562:Membrane Glycoproteins / Q000235:genetics / Q000276:immunology*; D051379:Mice; D008810:Mice, Inbred C57BL; D011897:Random Allocation; D020942:Shiitake Mushrooms / Q000737:chemistry; D016019:Survival Analysis; D014162:Transfection; D058951:gp100 Melanoma Antigen
chemical_list: D000276:Adjuvants, Immunologic; D000972:Antineoplastic Agents, Phytogenic; D019496:Cancer Vaccines; D008562:Membrane Glycoproteins; C548637:PMEL protein, human; C548642:Pmel protein, mouse; D058951:gp100 Melanoma Antigen; D007912:Lentinan